<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="161">
  <stage>Registered</stage>
  <submitdate>10/08/2005</submitdate>
  <approvaldate>11/08/2005</approvaldate>
  <actrnumber>ACTRN12605000127606</actrnumber>
  <trial_identification>
    <studytitle>Botulinum toxin A and the neglected upper limb in children with hemiplegic cerebral palsy</studytitle>
    <scientifictitle>The use of the assessment of motor and process skills (AMPS) in detecting a change in participation level function after botulinum toxin A injection in the upper limb of children with hemiplegic cerebral palsy</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Hemiplegic cerebral palsy</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Botulinum toxin A (Botox) injection into the affected upper limb followed by 4 weeks of intensive occupational therapy (intervention)</interventions>
    <comparator>Intensive occupational therapy alone (control)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Assessment of motor and process skills (AMPS)</outcome>
      <timepoint>At baseline, one month, three months, and six months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Neurorehabiltation examination </outcome>
      <timepoint>Baseline, 1, 3, 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pediatric quality of life (PEDSQoL)</outcome>
      <timepoint>Baseline 3, 6, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain scale</outcome>
      <timepoint>Baseline, 1, 3, 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Child self perception profile </outcome>
      <timepoint>Baseline, 3, 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Economic evaluation questionnaire</outcome>
      <timepoint>Baseline, 3, 6, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Goal attainment scale (GAS) </outcome>
      <timepoint>Baseline, 1, 3, 6, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pediatric evaluation of disability inventory (PEDI)</outcome>
      <timepoint>Baseline, 3, 6, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Child health questionnaire</outcome>
      <timepoint>Baseline, 3, 6, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lifestyle assessment questionnaire</outcome>
      <timepoint>Baseline, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehabilitation management questionnaire</outcome>
      <timepoint>Baseline, 1, 3, 6, 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Children aged between 3-16 years of aged diagnosed with hemiplegic cerebral palsy, registered on the South Australian Cerebral Palsy register, elbow extension to neutral, wrist extension to 30 degrees past neutral with fingers extended, supination of forearm to 30 degrees past neutral, thumb extension to neutral, can initiate finger movements, tone on a modified Ashworth Scale &gt;= 2/4 in at least one upper limb joint.</inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>16</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Infection at the proposed injection site, Myasthenia Gravis, Eaton Lambert Syndrome, botulinum toxin A injection in a lower limb within the previous 6 months or upper limb within the previous 12 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealed in sealed opaque envelopes and revealed to the investigator by a person external to the study investigators</concealment>
    <sequence>Computer-generated table of random numbers</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>44</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Maria Crotty</primarysponsorname>
    <primarysponsoraddress>Department of Rehabilitation and Aged Care Flinders University Repatriation General Hospital Daws Rd Daw Park SA 5041</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Financial Markets Foundation for Children,</fundingname>
      <fundingaddress>foundationforchildren@afma.com.au</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Allergan Australia</fundingname>
      <fundingaddress>77 Ridge Street
Gordon, NSW 2072</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Flinders University/Flinders Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Women's and Children's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof. Maria Crotty</name>
      <address>Department of Rehabilitation and Aged Care
Flinders University
Repatriation General Hospital
Daws Rd
Daw Park SA 5041</address>
      <phone>+61 8 82751103</phone>
      <fax>+61 8 82751130</fax>
      <email>maria.crotty@rgh.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof. Maria Crotty</name>
      <address>Department of Rehabilitation and Aged Care
Flinders University
Repatriation General Hospital
Daws Rd
Daw Park SA 5041</address>
      <phone>+61 8 82751103</phone>
      <fax>+61 8 82751130</fax>
      <email>maria.crotty@rgh.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>